1 Min Read
March 7 (Reuters) - Summit Therapeutics Plc:
* SUMMIT EXPANDS ENROLMENT IN PHASEOUT DMD PHASE 2 CLINICAL TRIAL TO INCLUDE PLANNED ADDITIONAL GROUP Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.